Otsuka’s Avanir Encouraged By First Peek At Treatment For Alzheimer’s Agitation
Phase III results from Avanir’s candidate for agitation in patients with Alzheimer’s disease offers some hope in a setting for which there is no specific treatment.
You may also be interested in...
Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.
The failure of BACE inhibitor lanabecestat was the latest setback in Lilly's Alzheimer's pipeline, but the company has been working in this area with almost no success for decades, yet still feels a commitment to keep trying, Lilly Research Labs President Daniel Skovronsky tells Scrip.
Denmark-based Lundbeck's plans to make Rexulti the first approved drug for agitation associated with dementia have been knocked back by mixed clinical data, necessitating another Phase III trial.